4 January 2017 - Orfadin to be available in a range of dosing alternatives, including first ever 20 mg dosage.

Sobi Canada announced today that Health Canada has approved Orfadin (nitisinone) capsules for the treatment of hereditary tyrosinaemia type-1 in combination with dietary restriction of tyrosine and phenylalanine. 

Hereditary tyrosinaemia is a rare genetic disease that affects infants and children. It is progressive and may result in liver, brain and kidney complications and can be fatal if untreated.

Read Sobi press release